Targeting muscle-enriched long non-coding RNA <i>H19</i> reverses pathological cardiac hypertrophy

Abstract

H19 is highly conserved and down-regulated in failing hearts from mice, pigs and humans. H19 gene therapy prevents and reverses experimental pressure-overload-induced heart failure. H19 acts as an anti-hypertrophic lncRNA and represents a promising therapeutic target to combat pathological cardiac remodelling.